About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker SRPT · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular D…
NCT07542314 · Duchenne Muscular Dystrophy
ELEVIDYS, Sirolimus
SRPT
Sarepta Therapeutics, Inc.
Phase 4Recruiting20Aug 31, 2027Registry ↗
Nov 10, 2026Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infus…
NCT06747273 · Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystro…
SRP-9004
SRPT
Sarepta Therapeutics, Inc.
Phase 1Terminated4Jun 18, 2025Registry ↗
Nov 10, 2026A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory P…
NCT05906251 · Limb Girdle Muscular Dystrophy
SRP-6004
SRPT
Sarepta Therapeutics, Inc.
Phase 1Terminated2Jun 13, 2025Registry ↗
Nov 10, 2026A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Mu…
NCT03992430 · Muscular Dystrophy, Duchenne
Eteplirsen
SRPT
Sarepta Therapeutics, Inc.
Phase 3Completed
was active, not recruiting
160Sep 7, 2026Registry ↗
Nov 6, 2026A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (…
NCT06241950 · Duchenne Muscular Dystrophy
delandistrogene moxeparvovec, imlifidase
SRPT
Sarepta Therapeutics, Inc.
Phase 1Terminated5Oct 10, 2025Registry ↗
Nov 2, 2026A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinica…
NCT06606340 · Duchenne Muscular Dystrophy
Eteplirsen, Golodirsen
SRPT
Sarepta Therapeutics, Inc.
—Enrolling by invitation300Dec 31, 2033Registry ↗
Oct 23, 2026An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in P…
NCT06270719 · Duchenne Muscular Dystrophy
Delandistrogene Moxeparvovec, Standard of Care
SRPT
Sarepta Therapeutics, Inc.
—Enrolling by invitation500Dec 31, 2028Registry ↗
Oct 19, 2026A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
NCT07536061 · Huntington's Disease
SRP-1005, Placebo
SRPT
Sarepta Therapeutics, Inc.
Phase 1Recruiting32Nov 30, 2027Registry ↗
Oct 5, 2026Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
NCT06138743 · Myotonic Dystrophy 1
SRP-1003 IV Infusion, Placebo IV Infusion
SRPT
Sarepta Therapeutics, Inc.
Phase 1/2Enrolling by invitation78Dec 31, 2026Registry ↗
Oct 5, 2026Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy…
NCT06131983 · Muscular Dystrophy, Facioscapulohumeral
SRP-1001 for Injection, Placebo
SRPT
Sarepta Therapeutics, Inc.
Phase 1/2Enrolling by invitation60Dec 31, 2028Registry ↗
Sep 11, 2026A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxepar…
NCT04626674 · Duchenne Muscular Dystrophy
delandistrogene moxeparvovec
SRPT
Sarepta Therapeutics, Inc.
Phase 1Recruiting83Dec 31, 2027Registry ↗
May 22, 2026A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (…
NCT05881408 · Duchenne Muscular Dystrophy
delandistrogene moxeparvovec, placebo
SRPT
Sarepta Therapeutics, Inc.
Phase 3Active, not recruiting148May 31, 2027Registry ↗
Mar 2, 2026A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9…
NCT06246513 · Limb-girdle Muscular Dystrophy
SRP-9003, Glucocorticoid
SRPT
Sarepta Therapeutics, Inc.
Phase 3Active, not recruiting17Mar 4, 2025Registry ↗
Feb 19, 2026A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in…
NCT05876780 · Limb Girdle Muscular Dystrophy
SRP-9003
SRPT
Sarepta Therapeutics, Inc.
Phase 1Active, not recruiting6Aug 28, 2028Registry ↗
Feb 6, 2026A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in…
NCT05967351 · Duchenne Muscular Dystrophy
delandistrogene moxeparvovec
SRPT
Sarepta Therapeutics, Inc.
Phase 3Enrolling by invitation400Oct 31, 2033Registry ↗
Jan 20, 2026Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-…
NCT03652259 · Limb-Girdle Muscular Dystrophy, Type 2E
SRP-9003
SRPT
Sarepta Therapeutics, Inc.
Phase 1/2Terminated6Jan 14, 2025Registry ↗
Nov 18, 2025Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dys…
NCT02500381 · Duchenne Muscular Dystrophy
SRP-4045, SRP-4053
SRPT
Sarepta Therapeutics, Inc.
Phase 3Completed228Nov 12, 2024Registry ↗
Nov 6, 2025A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1…
NCT04475926 · Limb-girdle Muscular Dystrophy
SRPT
Sarepta Therapeutics, Inc.
—Active, not recruiting205Sep 5, 2030Registry ↗
Sep 4, 2025A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-90…
NCT06597656 · Duchenne Muscular Dystrophy
delandistrogene moxeparvovec, Plasmapheresis
SRPT
Sarepta Therapeutics, Inc.
Phase 1Terminated3Aug 5, 2025Registry ↗
Aug 6, 2025A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants
NCT06952686 · Muscular Dystrophies, Limb-Girdle
SRP-9005, Corticosteroid
SRPT
Sarepta Therapeutics, Inc.
Phase 3Withdrawn0Nov 30, 2030Registry ↗
Jul 8, 2025A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (…
NCT05096221 · Duchenne Muscular Dystrophy
delandistrogene moxeparvovec, placebo
SRPT
Sarepta Therapeutics, Inc.
Phase 3Completed126Oct 4, 2023Registry ↗
Mar 10, 2025Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (P…
NCT04004065 · Duchenne Muscular Dystrophy
Vesleteplirsen
SRPT
Sarepta Therapeutics, Inc.
Phase 2Terminated62Oct 30, 2023Registry ↗
Nov 14, 2024A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for…
NCT03769116 · Muscular Dystrophy, Duchenne
delandistrogene moxeparvovec, placebo
SRPT
Sarepta Therapeutics, Inc.
Phase 1/2Completed41Dec 8, 2020Registry ↗
Nov 14, 2024A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in…
NCT03375164 · Duchenne Muscular Dystrophy
delandistrogene moxeparvovec
SRPT
Sarepta Therapeutics, Inc.
Phase 1/2Completed4Apr 25, 2023Registry ↗
Sep 19, 2024An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Stu…
NCT03675126 · Muscular Dystrophy, Duchenne
SRP-5051
SRPT
Sarepta Therapeutics, Inc.
Phase 1/2Terminated15Aug 25, 2021Registry ↗
Sep 19, 2024An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
NCT03532542 · Duchenne Muscular Dystrophy
Casimersen, Golodirsen
SRPT
Sarepta Therapeutics, Inc.
Phase 3Terminated171Jul 26, 2023Registry ↗
Aug 18, 2023A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne…
NCT03985878 · Duchenne Muscular Dystrophy
Eteplirsen
SRPT
Sarepta Therapeutics, Inc.
Phase 2Terminated15Aug 31, 2022Registry ↗
Jun 15, 2023A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in P…
NCT01976091 · Limb-Girdle Muscular Dystrophy, Type 2D
SRP-9004
SRPT
Sarepta Therapeutics, Inc.
Phase 1/2Completed6Mar 14, 2019Registry ↗
Jul 6, 2022A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Ve…
NCT03375255 · Muscular Dystrophy, Duchenne
SRP-5051
SRPT
Sarepta Therapeutics, Inc.
Phase 1Completed15Aug 19, 2019Registry ↗
Dec 9, 2021Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 5…
NCT03218995 · Duchenne Muscular Dystrophy
Eteplirsen
SRPT
Sarepta Therapeutics, Inc.
Phase 2Completed15Mar 10, 2021Registry ↗
May 17, 2021Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystr…
NCT02530905 · Duchenne Muscular Dystrophy
SRP-4045, Placebo
SRPT
Sarepta Therapeutics, Inc.
Phase 1Completed12Oct 3, 2018Registry ↗
May 13, 2021rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies
NCT02710500 · Dysferlinopathy
rAAVrh74.MHCK7.DYSF.DV
SRPT
Sarepta Therapeutics, Inc.
Phase 1Completed2Jul 2019Registry ↗
Jan 25, 2021Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
NCT02420379 · Duchenne Muscular Dystrophy (DMD)
eteplirsen
SRPT
Sarepta Therapeutics, Inc.
Phase 2Completed33Dec 17, 2018Registry ↗
Jan 25, 2021Study of Eteplirsen in DMD Patients
NCT02255552 · Duchenne Muscular Dystrophy (DMD)
eteplirsen
SRPT
Sarepta Therapeutics, Inc.
Phase 3Completed109Jun 14, 2019Registry ↗
Oct 19, 2020Phase I/II Study of SRP-4053 in DMD Patients
NCT02310906 · Duchenne Muscular Dystrophy
Placebo, SRP-4053
SRPT
Sarepta Therapeutics, Inc.
Phase 1/2Completed39Mar 25, 2019Registry ↗
Mar 30, 2020Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
NCT02286947 · Muscular Dystrophy, Duchenne
Eteplirsen
SRPT
Sarepta Therapeutics, Inc.
Phase 2Completed24Apr 21, 2017Registry ↗
Mar 30, 2020Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular…
NCT01540409 · Duchenne Muscular Dystrophy (DMD)
AVI-4658 (Eteplirsen)
SRPT
Sarepta Therapeutics, Inc.
Phase 2Completed12Apr 15, 2016Registry ↗
Mar 30, 2020Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy…
NCT01396239 · Duchenne Muscular Dystrophy
AVI-4658 (Eteplirsen), Placebo
SRPT
Sarepta Therapeutics, Inc.
Phase 2Completed12Feb 2012Registry ↗
Oct 6, 2015Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystro…
NCT00844597 · Duchenne Muscular Dystrophy
AVI-4658 for Injection
SRPT
Sarepta Therapeutics, Inc.
Phase 1/2Completed19Jun 2010Registry ↗

39 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 10:03 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances